🔗 Share this article

As the US proceeds with historic changes to its vaccination schedules, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations throughout the global health crisis and has focused upon alleged fatalities following Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Schedule

Agency leaders had intended to announce sweeping revisions to the childhood vaccine schedule recently, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of alignment with a large portion of the international standard with insufficient data for benefit. The planned update has been postponed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to present at the event. She was recently named acting director of the FDA’s CDER, the fifth person to head the center this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US to become more similar to the Danish model, a society with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – typically the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Expertise

The appointee has no obvious track record in pharmaceutical research, approval processes or management, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She has no expertise in drug approvals.”

Past directors of CBER would “understand legal statutes and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who ran CBER have had.”

This division has an vast portfolio at the agency, she emphasized.

“Everybody just focuses on the new drug program, but the generic program clears thousands of generic drugs. There’s a biologic copycat branch, OTC medication office and so forth, and all of those need to be supervised,” Woodcock explained. “The area you neglect, that is the part that I always told people is going to bite you.”

There is also, a substantial administrative component to the role, which supervises in excess of 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Policies

When asked about inquiries about Høeg’s qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “concerns are based on inaccurate assumptions”.

“Her resume is consistent with the duties of her role,” the spokesperson stated, noting the months Dr. Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s new priority voucher program, a controversial rapid therapy clearance system that reportedly troubled her former heads. “By what process are these drugs being picked for this fast-track system? Who makes the decisions?” Howard asked. “There’s a lot of secrecy happening at the agency right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards less stringent oversight of pharmaceuticals, aside from shots.”

Established Past Work on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, past, critics observe. She authored a study using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are more dangerous than they are.

Among her “wish list” for the new federal leadership featured changing guidelines for recently developed shots and ending “unnecessary” immunizations, she stated post-election on a audio program. At the agency, Høeg has according to sources proposed barring teenage boys from getting Covid vaccines.

“She’s an thorough dogmatist who commences with her conclusions and tailors the evidence to retrofit the science in a very misleading, untruthful way,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg joined other skeptics, {like|